Online inquiry

IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10216MR)

This product GTTS-WQ10216MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets RHD gene. The antibody can be applied in prevention of feto-maternal allo-immunization in RhD- women research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001127691.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6007
UniProt ID Q02161
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10216MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5224MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ4660MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ14025MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ1749MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ12802MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ9205MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ4842MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ2521MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 334
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW